News & Analysis on Clinical Trial Services & Contract Research And Development
People on the move
By Melissa Fassbender
- Last updated on
Certara has created a new role – senior vice president of health economics and education for which it has hired Sandy Allerheiligen, Ph.D.
“Our goals as scientists and professionals in the biopharma industry are to develop and deliver safe and effective therapies for all patients. To accomplish these goals, we need to bring both the patient and the payer into the conversation through increased transparency and shared objectives,” Allerheiligen told Outsourcing-Pharma.com.
Allerheiligen references what Dr. Mike Rawlins, chairman of the National Institute for health and Clinical Excellence, has termed the Fourth Hurdle: patient access, value, and affordability.
As she explained, her role will be to help Certara work with its partners to overcome that fourth hurdle “by extending the company’s strengths in pharmacometrics and other quantitative analyses and connecting them to health economics and real-world evidence.”
Allerheiligen was previously the vice president of data sciences and predictive and economic modeling, Center for Observational and Real-world Evidence at Merck.